Patents Assigned to Novartis Vaccines and Diagnostics, Inc.
  • Patent number: 8529906
    Abstract: The invention provides, inter alia, immunogenic compositions comprising a first antigen, at least two adjuvants, wherein a first adjuvant comprises a polymer derived from poly(lactides) and/or poly(lactide-co-glycolides), and wherein a second adjuvant comprises an imidazoquinoline, wherein said first antigen is encapsulated within, adsorbed or conjugated to, co-lyophilized or mixed with said first adjuvant, and a pharmaceutically acceptable excipient, wherein said composition elicits a cellular immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions, methods for producing a cytotoxic-T lymphocyte (CTL) response in a vertebrate subject, and methods of immunization.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: September 10, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Manmohan Singh
  • Patent number: 8518694
    Abstract: A nucleic acid vector comprising: (i) a promoter; (ii) a sequence encoding a HML-2 polypeptide operably linked to said promoter; and (iii) a selectable marker. Preferred vectors comprise: (I) a eukaryotic promoter; (ii) a sequence encoding a HML-2 polypeptide downstream of and operably linked to said promoter, (iii) a prokaryotic selectable marker; (iv) a prokaryotic origin of replication; and (v) a eukaryotic transcription terminator downstream of and operably linked to said sequence encoding a HML-2 polypeptide. Vectors of the invention are particularly useful for expression of HML-2 polypeptides either in vitro (e.g. for later purification). Or in vivo (e.g. for nucleic acid immunization). They are well suited to nucleic acid immunization against prostrate tumors. A preferred HML-2 is PCAV, which is located in chromosome 22 at 20.428 megabases (22q11.2).
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: August 27, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Stephen Hardy, John Donnelly, Jan zur Megede
  • Publication number: 20130195898
    Abstract: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(?-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided.
    Type: Application
    Filed: September 15, 2012
    Publication date: August 1, 2013
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Gary S. Ott, John Donnelly, Jina Kazzaz, Mildred Ugozzoli, Manmohan Singh, John Barackman
  • Publication number: 20130196314
    Abstract: A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.
    Type: Application
    Filed: August 2, 2012
    Publication date: August 1, 2013
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Joerg Kaufmann, Greg Harrowe, Christoph Reinhard, Sanmao Kang
  • Publication number: 20130195923
    Abstract: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(?-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided.
    Type: Application
    Filed: September 14, 2012
    Publication date: August 1, 2013
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Derek O'Hagan, Gary S. Ott, John Donnelly, Jina Kazzaz, Mildred Ugozzoli, Manmohan Singh, John Barackman
  • Patent number: 8481050
    Abstract: A tissue culture system for production of infectious hepatitis C virus is described. In particular, the invention provides recombinant monocistronic and bicistronic genomic constructs for production of virus, including constructs for production of wild-type HCV type 2a strain JFH1 and constructs for production of chimeric viruses comprising HCV proteins from strain JFH1 and a second HCV isolate. Constructs of the invention also include a reporter gene to facilitate measurement of RNA replication and viral infectivity in cultures. The cell culture system may also include various factors that improve viral replication or infectivity. In addition, a neutralization assay using HCV grown in cell culture is described.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: July 9, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Qui-Lim Choo, Jang Han, Michael Houghton, Taewoo Kwon, Hyun Chul Song, Yifei Zhu
  • Patent number: 8475808
    Abstract: Recombinant production of immunogenic West Nile Virus (WNV) proteins is described. These proteins, heterodimers comprising the proteins, fusions thereof, polynucleotides encoding the proteins, and combinations thereof, as well as antibodies produced therefrom, can be used in immunogenic compositions for preventing, treating and diagnosing WNV infection. Also described are highly sensitive ELISA and strip immunoassay methods for detecting the presence of WNV in biological samples.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: July 2, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: William Andrews, David Chien, Qui-Lim Choo, Stephen Coates, Doris Coit, Charles Harrington, Susan Hilt, Michael Houghton, Angelica Medina-Selby, Sergio Pichuantes, Yiu-Lian Fong
  • Patent number: 8470334
    Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Methods of diagnosis, treatment and prevention using the polypeptides are also provided.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: June 25, 2013
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Susan W. Barnett, Indresh K. Srivastava
  • Patent number: 8460873
    Abstract: The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: June 11, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Giulia Kennedy
  • Publication number: 20130129740
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Application
    Filed: August 30, 2012
    Publication date: May 23, 2013
    Applicants: J. Craig Venter Institute, Novartis Vaccines and Diagnostics, Inc.
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Hervé Tettelin, Claire Fraser
  • Patent number: 8431139
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Grant
    Filed: May 16, 2006
    Date of Patent: April 30, 2013
    Assignees: Novartis Vaccines and Diagnostics, Inc., J. Craig Venter Institute
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
  • Publication number: 20130096103
    Abstract: The invention provides novel compositions comprising imidazoquinoline compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).
    Type: Application
    Filed: June 19, 2012
    Publication date: April 18, 2013
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Nicholas VALIANTE, Feng Xu, Xiaodong Lin, Daniel Chu, Xiaojing Michael Wang
  • Publication number: 20130095552
    Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.
    Type: Application
    Filed: November 27, 2012
    Publication date: April 18, 2013
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Novartis Vaccines and Diagnostics, Inc.
  • Patent number: 8415382
    Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: April 9, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Abran Costales, Teresa Hansen, Barry H. Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Joelle Verhagen
  • Publication number: 20130085264
    Abstract: Novel methods and immunodiagnostic test kits for the detection of hantavirus infection are disclosed. The methods and kits employ combinations of recombinant N and/or G1 antigens from at least six different hantavirus serotypes, including Hantann (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV). Additional hantavirus antigens from these and other hantavirus types may also be present. The methods provide for highly accurate results and allow the detection of infection so that treatment can be administered and death avoided.
    Type: Application
    Filed: December 5, 2012
    Publication date: April 4, 2013
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Novartis Vaccines and Diagnostics, Inc.
  • Patent number: 8388942
    Abstract: Improved methods for purification and recovery of interferon-beta (IFN-?) and compositions comprising substantially monomeric IFN-? are provided. In one purification method, substantially purified IFN-? or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (HCl) solution. Renaturation of the protein occurs by dilution with a suitable buffer. A similar purification method absent the precipitation step is also provided. Following renaturation of the IFN-?, residual guanidine HCl is removed by diafiltration or dialysis with a pharmaceutically acceptable buffer to prepare pharmaceutical compositions comprising substantially monomeric IFN-?.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: March 5, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Sidney N Wolfe, Bret A Shirley, Susan Babuka, Dennis Fordham, Irina Esikova
  • Patent number: 8377446
    Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: February 19, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Marco Soriani, Isabella Santi
  • Publication number: 20130011405
    Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
    Type: Application
    Filed: September 12, 2012
    Publication date: January 10, 2013
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst, Sharon Lea Aukerman, Daniel E. Lopes de Menezes
  • Patent number: 8333958
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: December 18, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Bret A Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • Publication number: 20120308569
    Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.
    Type: Application
    Filed: June 7, 2012
    Publication date: December 6, 2012
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Vivien W. CHAN, Jaime Escobedo, Pablo Dominguez Garcia, Rhonda Hansen, Joerg Kaufmann, Giulia C. Kennedy, George Lamson, Edward J. Moler, Filippo Randazzo, Christoph Reinhard, Julie Sudduth-Klinger